Last reviewed · How we verify
SODIUM PHENYLACETATE
SODIUM PHENYLACETATE is a drug. It is currently FDA-approved (first approved 1987) for Acute hyperammonemia and associated encephalopathy.
Sodium phenylacetate and sodium benzoate provide alternative pathways for nitrogen disposal in patients with urea cycle disorders.
Sodium phenylacetate is a small molecule that acts as a glutamine sequestering agent. It has been studied in clinical trials for various conditions, including inflammation, acute pancreatitis, low back pain, renal insufficiency, and hepatic insufficiency.
At a glance
| Generic name | SODIUM PHENYLACETATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1987 |
Mechanism of action
In patients with urea cycle disorders, sodium phenylacetate and sodium benzoate help remove waste nitrogen through alternative metabolic pathways. Phenylacetate forms phenylacetylglutamine, which is excreted by the kidneys, while benzoate forms hippuric acid, also excreted by the kidneys.
Approved indications
- Acute hyperammonemia and associated encephalopathy
Common side effects
- vomiting
- hyperglycemia
- hypokalemia
- convulsions
- mental impairment
Drug interactions
- Penicillin
- Probenecid
- Valproic Acid
- Corticosteroids
Key clinical trials
- Counterpain PXM Versus Diclofenac Versus Piroxicam (PHASE3)
- Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO) (PHASE2)
- Intramuscular Versus Rectal Diclofenac for Pain Relief After Cesarean Section in Women (PHASE4)
- A Comparison of Recovery After Impacted Wisdom Tooth Removal (PHASE3)
- Efficacy of Genicular Block on Total Knee Arthroplasty Surgery (NA)
- Gabapentin and Diclofenac Sodium Comparison for Post-Operative Pain Relief (NA)
- The Effect of Different Intracanal Medicaments on Periapical Lesion Healing (NA)
- A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-123 After Intravenous Infusion in Japanese Healthy Adult Male Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SODIUM PHENYLACETATE CI brief — competitive landscape report
- SODIUM PHENYLACETATE updates RSS · CI watch RSS
Frequently asked questions about SODIUM PHENYLACETATE
What is SODIUM PHENYLACETATE?
How does SODIUM PHENYLACETATE work?
What is SODIUM PHENYLACETATE used for?
When was SODIUM PHENYLACETATE approved?
What development phase is SODIUM PHENYLACETATE in?
What are the side effects of SODIUM PHENYLACETATE?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing